Mydecine

Mydecine's Q1 2023 Reports Shows Decline In Assets And R&D, Increase In Net Loss And Accumulated Deficit
Understanding The Psilocybin Supply Chain: Every Production Method Explained
Mydecine Announces 1-for-50 Reverse Stock Split
Understanding The Psilocybin Supply Chain: Every Production Method Explained
Mydecine Announces 1-for-50 Reverse Stock Split
Psyched: Atai Raises $157M, Silo Wellness Goes Public, Mydecine Completes Export Of 'Magic Mushrooms'
4 Psychedelics Experts On Adoption In Mainstream Medicine: 'A Mental Health Revolution'

Mydecine Recent News

The Migration Saga: From Beverage To Cannabis (And Vice Versa)
Over the past year, many cannabis businesses opted to reinforce their teams by hiring beverage experts.
'Psyched': MindMed Eyes NASDAQ, Ann Arbor Decriminalizes, Mydecine Launches New App
Ann Arbor Votes To Decriminalize Entheogenic Plants and Fungi
'Psyched': Compass IPO, UC Berkeley's Psychedelics Center, Jaguar Health's Entheogen Initiative
Compass IPO Begins Trading on NASDAQ Following a NASDAQ filing earlier this month, UK-based psychedelics research company Compass Pathways began trading under the symbol CMPS on Friday.
Mydecine Snags License To Produce, Sell and Export Natural Psilocybin For Research
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) announced Wednesday that it has begun to exercise its
'Psyched': Atai Launches DMT Subsidiary, NeuroPharm Collaborates With Dutch University
ATAI Launches Subsidiary Focused on DMT
'Psyched': Atai Buys Kures, Beckley Psytech Raises $3.7M, Mydecine Acquires NeuroPharma
PSYCHED is now weekly! As the psychedelics industry grows, so does the need for news. For this reason, our column covering the most important developments in medicinal psychedelics is now a weekly feature. 
'Psyched': Silo Wellness To Go Public, MindMed Adds DMT To Research Portfolio, Champignon Closes $11M Raise, Mydecine Launches New Research Partnership
Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry.
'Psyched': New Leaf Brands Changes Name To Mydecine, Numinus Debuts On TSXV, MindMed To Research MDMA-LSD Interactions
Psyched is a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry.